Physician profile
Barbara E Quattrone
NPI 1093791972
$2,053.28
in general payments reported to CMS, 2019-2025
30 companies · $36.74 in 2025
The $36.74 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $349 · 2021: $509 · 2022: $494 · 2023: $167 · 2024: $39.67 · 2025: $36.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $388.07 | 2019-2022 | |
| Amgen INC. | $164.53 | 2019-2022 | |
| Vertos Medical, INC. | $161.88 | 2022 | |
| Abbvie INC. | $160.34 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $151.23 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $113.77 | 2019-2022 | |
| Medtronic, INC. | $95.82 | 2023-2024 | Synchromedii, Vanta Adaptivestim, Intellis Adaptivestim |
| Abbott Laboratories | $93.85 | 2019-2023 | Proclaim |
| Alnylam Pharmaceuticals INC. | $91.28 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $80.70 | 2021-2022 | |
| Eisai INC. | $60.17 | 2020-2021 | |
| Piramal Critical Care | $56.38 | 2019-2022 | |
| Mdd US Operations, LLC | $43.31 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.81 | 2022 | |
| Lilly USA, LLC | $37.60 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.83 | 2021 | |
| Lundbeck LLC | $30.99 | 2022 | |
| Horizon Therapeutics Plc | $30.39 | 2019 | |
| Tanabe Pharma America, INC. | $28.66 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $27.07 | 2023 | Iovera |
| Ipsen Biopharmaceuticals, INC | $24.78 | 2023 | Dysport |
| Saol Therapeutics INC. | $24.36 | 2019 | |
| Medtronic USA, INC. | $19.69 | 2019 | |
| Stimwave Technologies Incorporated | $15.82 | 2019 | |
| Boston Scientific Corporation | $14.39 | 2019 | |
| Pacira Therapeutics, INC. | $13.51 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.40 | 2020 | |
| Sarepta Therapeutics, INC. | $13.19 | 2020 | |
| Redhill Biopharma INC. | $11.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Quattrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.